| Male patients (n = 25) | Female patients (n = 18) | |
| Number of patients (%) | Number of patients (%) | |
| Demographic characteristics | ||
| Age (mean ± SD) | 41.94±10.83 years | 52.48±17.50 years |
| Range of age | 21–62 years | 19–74 years |
| Most common CNS manifestations | ||
| A) Total no. of patients with cerebrovascular events | 6 (20%) | 5 (28%) |
| TIA | 5 (20%) | 3 (17%) |
| Stroke | 6 (24%) | 5 (28%) |
| Age at onset (mean ± SD) | 33.64±13.65 yrs | 53.68±11.71 yrs |
| Recurrence | 6 (24%) | 4 (22%) |
| First episode during ERT | 0 (0%) | 0 (0%) |
| B) Total number of patients with minor neurological manifestations | 15 (60%) | 12 (67%) |
| Diplopia | 5 (20%) | 3 (17%) |
| Migraine/recurrent headache | 5 (20%) | 5 (28%) |
| Vertigo | 8 (32%) | 2 (11%) |
| Hearing loss | 9 (36%) | 6 (33%) |
| Reported cognitive problems | 3 (12%) | 4 (22%) |
| Total percentage of patients with any kind of clinical CNS manifestation | 16 (64%) | 13 (72%) |
| Total percentage of patients without any kind of clinical CNS manifestation | 9 (36%) | 5 (28%) |
| Clinical outcome | ||
| Rankin scale ⩾2 | 9 (36%) | 4 (22%) |
| EuroQol ⩾3 | 4 (16%) | 4 (22%) |
CNS, central nervous system; ERT, enzyme replacement therapy; manifest., manifestations; No., number; SD, standard deviation; TIA, transitory ischaemic attack.